McKesson (NYSE:MCK) Lowered to Hold Rating by Wall Street Zen

McKesson (NYSE:MCK) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other analysts have also recently weighed in on MCK. Barclays raised their price target on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. TD Cowen upped their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Evercore reissued an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, Mizuho raised their price objective on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research note on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $960.93.

McKesson Trading Down 0.3%

NYSE:MCK opened at $941.51 on Friday. McKesson has a 12 month low of $637.00 and a 12 month high of $999.00. The firm has a market cap of $115.33 billion, a P/E ratio of 27.08, a price-to-earnings-growth ratio of 1.52 and a beta of 0.38. The stock has a 50 day moving average of $893.90 and a two-hundred day moving average of $824.34.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts forecast that McKesson will post 32.77 earnings per share for the current year.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,868 shares of company stock valued at $3,743,820. 0.08% of the stock is currently owned by insiders.

Institutional Investors Weigh In On McKesson

A number of large investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its stake in shares of McKesson by 46.3% in the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock worth $1,438,000 after acquiring an additional 798 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of McKesson in the first quarter valued at $233,000. Sivia Capital Partners LLC lifted its stake in McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after purchasing an additional 300 shares during the period. ABN Amro Investment Solutions acquired a new stake in shares of McKesson in the 2nd quarter valued at $1,663,000. Finally, Clearstead Trust LLC grew its stake in McKesson by 52.8% during the second quarter. Clearstead Trust LLC now owns 55 shares of the company’s stock worth $40,000 after buying an additional 19 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.